In this health economics model, it was predicted that by utilizing the Elecsys AMH Plus immunoassay for diagnosing women with PCOS, the UK NHS would benefit by increasing the number of women diagnosed with PCOS, reducing the costs associated with PCOS diagnosis, and reducing the costs associated with common secondary comorbidities. Here, AMH is linked to polycystic ovary syndrome.